Astellas To Develop Beta-Secretase Inhibitor For Alzheimer’s In Deal With CoMentis
This article was originally published in The Pink Sheet Daily
Executive Summary
$760 million gets Japanese pharma a Phase I compound and research into more potential disease modifying therapies for Alzheimer’s.